{"id":42545,"date":"2025-09-30T14:49:53","date_gmt":"2025-09-30T06:49:53","guid":{"rendered":"https:\/\/flcube.com\/?p=42545"},"modified":"2025-09-30T14:49:54","modified_gmt":"2025-09-30T06:49:54","slug":"changchun-genescience-secures-china-approval-for-long%e2%80%91acting-fsh%e2%80%91ctp-injection","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42545","title":{"rendered":"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection"},"content":{"rendered":"\n<p><strong>China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd.<\/strong> announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion protein injection, marketed as <strong>Follitropin Alpha\u202fN02 Injection<\/strong>, has received official marketing approval in China. The decision follows the company\u2019s successful submission to the National Medical Products Administration (NMPA) and marks a significant advance in assisted\u2011reproductive\u2011technology (ART) options for Chinese patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-indication\">Clinical Indication<\/h2>\n\n\n\n<p>Follitropin Alpha\u202fN02 is approved for use <strong>in combination with a gonadotropin\u2011releasing hormone (GnRH) antagonist<\/strong> during controlled ovarian stimulation (COS). The single subcutaneous injection replaces the traditional seven\u2011day daily FSH regimen, offering a more convenient and potentially cost\u2011effective approach to inducing multiple follicle development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<p>The world\u2019s first long\u2011acting FSH, <strong>Elonva<\/strong>, received EU approval in 2010. In China, patients have long been burdened by daily injections, underscoring the critical need for long\u2011acting stimulation therapies. GeneScience pioneered the country\u2019s first domestically produced recombinant human FSH in 2015, but that formulation remained short\u2011acting. With infertility prevalence now at <strong>18.2\u202f%<\/strong> in China, demand for streamlined ART solutions is rising sharply.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>The approval positions Changchun GeneScience as a key player in the rapidly expanding Chinese reproductive\u2011health market. By delivering a single\u2011dose, long\u2011acting FSH product, the company addresses both clinical efficacy and patient adherence, potentially reshaping standard COS protocols nationwide.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42546,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[358,15],"class_list":["post-42545","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-genescience-pharmaceutical","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion protein injection, marketed as Follitropin Alpha\u202fN02 Injection, has received official marketing approval in China. The decision follows the company\u2019s successful submission to the National Medical Products Administration (NMPA) and marks a significant advance in assisted\u2011reproductive\u2011technology (ART) options for Chinese patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42545\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion protein injection, marketed as Follitropin Alpha\u202fN02 Injection, has received official marketing approval in China. The decision follows the company\u2019s successful submission to the National Medical Products Administration (NMPA) and marks a significant advance in assisted\u2011reproductive\u2011technology (ART) options for Chinese patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42545\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-30T06:49:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-30T06:49:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3006.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection\",\"datePublished\":\"2025-09-30T06:49:53+00:00\",\"dateModified\":\"2025-09-30T06:49:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3006.webp\",\"keywords\":[\"GeneScience Pharmaceutical\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42545#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42545\",\"name\":\"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3006.webp\",\"datePublished\":\"2025-09-30T06:49:53+00:00\",\"dateModified\":\"2025-09-30T06:49:54+00:00\",\"description\":\"China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion protein injection, marketed as Follitropin Alpha\u202fN02 Injection, has received official marketing approval in China. The decision follows the company\u2019s successful submission to the National Medical Products Administration (NMPA) and marks a significant advance in assisted\u2011reproductive\u2011technology (ART) options for Chinese patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42545\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3006.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3006.webp\",\"width\":1080,\"height\":608,\"caption\":\"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42545#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion protein injection, marketed as Follitropin Alpha\u202fN02 Injection, has received official marketing approval in China. The decision follows the company\u2019s successful submission to the National Medical Products Administration (NMPA) and marks a significant advance in assisted\u2011reproductive\u2011technology (ART) options for Chinese patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42545","og_locale":"en_US","og_type":"article","og_title":"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection","og_description":"China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion protein injection, marketed as Follitropin Alpha\u202fN02 Injection, has received official marketing approval in China. The decision follows the company\u2019s successful submission to the National Medical Products Administration (NMPA) and marks a significant advance in assisted\u2011reproductive\u2011technology (ART) options for Chinese patients.","og_url":"https:\/\/flcube.com\/?p=42545","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-30T06:49:53+00:00","article_modified_time":"2025-09-30T06:49:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3006.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42545#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42545"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection","datePublished":"2025-09-30T06:49:53+00:00","dateModified":"2025-09-30T06:49:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42545"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42545#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3006.webp","keywords":["GeneScience Pharmaceutical","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42545#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42545","url":"https:\/\/flcube.com\/?p=42545","name":"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42545#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42545#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3006.webp","datePublished":"2025-09-30T06:49:53+00:00","dateModified":"2025-09-30T06:49:54+00:00","description":"China\u2011based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long\u2011acting recombinant human follicle\u2011stimulating hormone\u2014CTP fusion protein injection, marketed as Follitropin Alpha\u202fN02 Injection, has received official marketing approval in China. The decision follows the company\u2019s successful submission to the National Medical Products Administration (NMPA) and marks a significant advance in assisted\u2011reproductive\u2011technology (ART) options for Chinese patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42545#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42545"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42545#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3006.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3006.webp","width":1080,"height":608,"caption":"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42545#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun GeneScience Secures China Approval for Long\u2011Acting FSH\u2011CTP Injection"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3006.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42545"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42545\/revisions"}],"predecessor-version":[{"id":42547,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42545\/revisions\/42547"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42546"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}